Drug · DIN 02467321
M-PREGABALIN
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 6, 2023; first marketed April 3, 2018.
- Drug Identification Number (DIN)
- 02467321
- Company (DIN owner)
- Mantra Pharma Inc.Brossard, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Capsule
- Route
- Oral
- Therapeutic class (ATC)
- Pregabalin N02BF02
- Class
- Human
- Record last updated
- October 14, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| PREGABALIN | 150 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 6, 2023: NOC 31797Abbreviated New Drug Submission (ANDS) · Administrative: Licensing Agreement Between Two Manufacturers
- August 17, 2017: NOC 19676Abbreviated New Drug Submission (ANDS) · Licensing agreement between two companies
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “m-pregabalin”. A notice may cover another product or only some lots: read it to see what it covers.
- M-Pregabalin 25mg Capsules (2019-08-21)August 21, 2019 · Drugs · Product safety · Type III
Other DINs named M-PREGABALIN
- DIN 02467291 · Marketed
- DIN 02467305 · Marketed
- DIN 02467313 · Marketed
- DIN 02541963 · Marketed
- DIN 02541939 · Approved
- DIN 02541947 · Approved
- DIN 02541955 · Approved